We know GCDX is NOT being used as a deception. GCDx is exactly what it appears to be.
If GCDx was a deception, that would mean Gartner is lying in the interviews, lying on Fundable, lying in his Arizona filings, and lying in his public responses to investor questions. Impossible, IMO -- there is no reason whatsoever for Gartner to lie in that manner.
Any tests sold by GCDx will be done independently from Radient. GCDx has no license agreement or contract with Radient.
As for Genway and/or GCDx purposely filing a trademark application with the intent of having it get rejected... that makes no sense at all. The simple answer is: "The Lung Cancer Test" is too generic a name to receive a trademark.
Radient still has a trademark for the name "Onko-Sure" but that doesn't matter. "Onko-Sure" was such a failure for Radient that anyone trying to sell the test now should distance themselves as far as possible from the name "Onko-Sure," IMO. I think Gartner is going out of his way to hide the fact that he is simply trying to sell DR-70.
